BRIEF-Axsome Therapeutics receives FDA fast track designation for axs-05 for alzheimer’s disease agitation
May 08, 2017 at 07:24 AM EDT
* Axsome therapeutics receives fda fast track designation for axs-05 for alzheimer’s disease agitation Source text for Eikon: Further company coverage:
